Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest Expenses (2016 - 2017)

IGC Pharma has reported Interest Expenses over the past 8 years, most recently at $60527.0 for Q4 2017.

  • Quarterly Interest Expenses rose 30.26% to $60527.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $60527.0 through Sep 2018, down 72.35% year-over-year, with the annual reading at $223464.0 for FY2017, 4.46% up from the prior year.
  • Interest Expenses was $60527.0 for Q4 2017 at IGC Pharma, up from $40832.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $390486.0 in Q1 2013 and troughed at $33928.0 in Q1 2016.
  • The 5-year median for Interest Expenses is $60848.5 (2014), against an average of $77837.0.
  • Year-over-year, Interest Expenses surged 1880.46% in 2013 and then crashed 85.13% in 2014.
  • A 5-year view of Interest Expenses shows it stood at $52502.0 in 2013, then rose by 18.01% to $61957.0 in 2014, then fell by 17.68% to $51000.0 in 2015, then dropped by 8.89% to $46465.0 in 2016, then soared by 30.26% to $60527.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Interest Expenses are $60527.0 (Q4 2017), $40832.0 (Q3 2017), and $44546.0 (Q2 2017).